Northern Trust Corp Sells 27,201 Shares of Sotera Health Company $SHC

Key Points

• Northern Trust Corp reduced its stake in Sotera Health Company by 2.0%, owning 1,307,166 shares valued at approximately $15.24 million after selling 27,201 shares in the 1st quarter.
• Several institutional investors have increased their stakes in Sotera Health, with Farther Finance Advisors LLC boosting its holdings by 4,881.9%, now owning 6,327 shares worth $70,000.
• Sotera Health reported $0.20 earnings per share for the quarter, exceeding analyst expectations, and noted a revenue increase of 6.4% year-over-year, setting FY 2025 EPS guidance between 0.750-0.820.

Northern Trust Corp trimmed its stake in shares of Sotera Health Company (NASDAQ:SHC - Free Report) by 2.0% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 1,307,166 shares of the company's stock after selling 27,201 shares during the quarter. Northern Trust Corp owned about 0.46% of Sotera Health worth $15,242,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Sculptor Capital LP bought a new stake in shares of Sotera Health during the 4th quarter valued at $68,400,000. Irenic Capital Management LP raised its holdings in shares of Sotera Health by 4.3% during the 4th quarter. Irenic Capital Management LP now owns 2,909,163 shares of the company's stock worth $39,797,000 after buying an additional 120,832 shares in the last quarter. Two Seas Capital LP raised its holdings in shares of Sotera Health by 624.0% during the 4th quarter. Two Seas Capital LP now owns 2,896,136 shares of the company's stock worth $39,619,000 after buying an additional 2,496,136 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in shares of Sotera Health by 140.8% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 2,624,750 shares of the company's stock worth $35,907,000 after buying an additional 1,534,666 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Sotera Health by 5.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,415,282 shares of the company's stock worth $16,502,000 after buying an additional 68,087 shares in the last quarter. 91.03% of the stock is currently owned by institutional investors.

Insider Transactions at Sotera Health

In other news, insider Michael P. Rutz sold 126,611 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $16.38, for a total value of $2,073,888.18. Following the completion of the sale, the insider owned 450,204 shares of the company's stock, valued at approximately $7,374,341.52. This represents a 21.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 55.12% of the stock is currently owned by insiders.

Sotera Health Price Performance

SHC traded down $0.37 on Tuesday, reaching $15.54. The stock had a trading volume of 340,941 shares, compared to its average volume of 1,353,301. Sotera Health Company has a fifty-two week low of $9.53 and a fifty-two week high of $16.99. The firm has a 50-day moving average of $13.44 and a 200-day moving average of $12.35. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 4.49. The company has a market capitalization of $4.41 billion, a price-to-earnings ratio of 194.34 and a beta of 1.83.

Sotera Health (NASDAQ:SHC - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.17 by $0.03. Sotera Health had a return on equity of 39.42% and a net margin of 2.14%.The business had revenue of $294.34 million during the quarter, compared to analysts' expectations of $275.81 million. During the same quarter in the prior year, the firm earned $0.19 EPS. The business's revenue for the quarter was up 6.4% compared to the same quarter last year. Sotera Health has set its FY 2025 guidance at 0.750-0.820 EPS. As a group, sell-side analysts anticipate that Sotera Health Company will post 0.61 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Barclays reissued an "overweight" rating on shares of Sotera Health in a report on Friday, August 8th. Wall Street Zen raised Sotera Health from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $16.00.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.